The DEA recently published its final rule (www.federalregister.gov) in the Federal Register that moved hydrocodone combination products (HCPs) from Schedule III to the more restrictive Schedule II, as was recommended by the HHS assistant secretary. The swell in HCP prescriptions can be …

READ FULL ARTICLE Curated publisher From Aafp